Contact
Location
Stacey Hall & MR5
Lab
​Box 800759, Health System
​Box 800759, Health System
Charlottesville, VA 22901
UVA Coulter Center Biomedical Frontiers Podcast

About

David Chen is the founding Managing Director of the Wallace H. Coulter Center for Translational Research at the University of Virginia. He began his career at ImClone Systems, where he worked closely with both European regulatory agencies as well as the FDA on Erbitux (now a Lilly company). He holds a Master of Science in Cell and Developmental Biology from Rutgers University/Robert Wood Johnson Medical School and an MBA from UVA’s Darden School of Business.

David is a Professor of Practice in the Department of Biomedical Engineering and Assistant Dean for Innovation & Entrepreneurship for the School of Engineering and Applied Science.  

Education

B.S. Biology, Liberty University, 1999

M.S. Cell and Developmental Biology, Rutgers University, 2002

M.B.A The Darden School of Business, 2006

"I love science and the process of discovery. I'm intrigued by the impact and social contributions of discovery through translational research, design, instruction, and business."

David Chen Managing Director of UVA's Coulter Center

Research Interests

Translational Research
Entrepreneurship
Technology Transfer

Courses Taught

BME 3030 Biomedical Engineering Design and Innovation in Medicine
BME 3040 - Regulation & Design of Biomedical Products
BME 4550 Experiential Learning for Your Future

Wallace H. Coulter Center for Translational Research

Over the last 18 years, the Wallace H. Coulter Center for Translational Research at the University of Virginia has funded 115 projects to realize its mission of “science serving humanity.” The Coulter Center awards approximately $900,000 each year to biomedical engineering faculty members and research collaborators from the School of Medicine, the School of Engineering and other areas of the University. They work together to develop new technologies that address unmet clinical needs, improve health care, and lead to commercially available products. 25 Coulter-funded startups have raised $750 million in private capital, enabling the flow of cutting-edge products and processes from labs into clinical practice.
Website